304 related articles for article (PubMed ID: 15753384)
1. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis.
Tan M; Li P; Klos KS; Lu J; Lan KH; Nagata Y; Fang D; Jing T; Yu D
Cancer Res; 2005 Mar; 65(5):1858-67. PubMed ID: 15753384
[TBL] [Abstract][Full Text] [Related]
2. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers.
Zhou X; Tan M; Stone Hawthorne V; Klos KS; Lan KH; Yang Y; Yang W; Smith TL; Shi D; Yu D
Clin Cancer Res; 2004 Oct; 10(20):6779-88. PubMed ID: 15501954
[TBL] [Abstract][Full Text] [Related]
3. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
Tan M; Li P; Sun M; Yin G; Yu D
Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
[TBL] [Abstract][Full Text] [Related]
4. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells.
Klos KS; Wyszomierski SL; Sun M; Tan M; Zhou X; Li P; Yang W; Yin G; Hittelman WN; Yu D
Cancer Res; 2006 Feb; 66(4):2028-37. PubMed ID: 16489002
[TBL] [Abstract][Full Text] [Related]
5. The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Xu W; Yuan X; Jung YJ; Yang Y; Basso A; Rosen N; Chung EJ; Trepel J; Neckers L
Cancer Res; 2003 Nov; 63(22):7777-84. PubMed ID: 14633703
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
7. Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin.
Takano A; Usui I; Haruta T; Kawahara J; Uno T; Iwata M; Kobayashi M
Mol Cell Biol; 2001 Aug; 21(15):5050-62. PubMed ID: 11438661
[TBL] [Abstract][Full Text] [Related]
8. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
[TBL] [Abstract][Full Text] [Related]
9. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
[TBL] [Abstract][Full Text] [Related]
10. RAFTK/Pyk2 tyrosine kinase mediates the association of p190 RhoGAP with RasGAP and is involved in breast cancer cell invasion.
Zrihan-Licht S; Fu Y; Settleman J; Schinkmann K; Shaw L; Keydar I; Avraham S; Avraham H
Oncogene; 2000 Mar; 19(10):1318-28. PubMed ID: 10713673
[TBL] [Abstract][Full Text] [Related]
11. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
Yu J; Henske EP
Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
[TBL] [Abstract][Full Text] [Related]
12. Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model.
Efferson CL; Winkelmann CT; Ware C; Sullivan T; Giampaoli S; Tammam J; Patel S; Mesiti G; Reilly JF; Gibson RE; Buser C; Yeatman T; Coppola D; Winter C; Clark EA; Draetta GF; Strack PR; Majumder PK
Cancer Res; 2010 Mar; 70(6):2476-84. PubMed ID: 20197467
[TBL] [Abstract][Full Text] [Related]
13. Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk.
Van Slyke P; Coll ML; Master Z; Kim H; Filmus J; Dumont DJ
Mol Cell Biol; 2005 May; 25(9):3831-41. PubMed ID: 15831486
[TBL] [Abstract][Full Text] [Related]
14. Csk homologous kinase associates with RAFTK/Pyk2 in breast cancer cells and negatively regulates its activation and breast cancer cell migration.
McShan GD; Zagozdzon R; Park SY; Zrihan-Licht S; Fu Y; Avraham S; Avraham H
Int J Oncol; 2002 Jul; 21(1):197-205. PubMed ID: 12063569
[TBL] [Abstract][Full Text] [Related]
15. Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation.
Karni R; Gus Y; Dor Y; Meyuhas O; Levitzki A
Mol Cell Biol; 2005 Jun; 25(12):5031-9. PubMed ID: 15923620
[TBL] [Abstract][Full Text] [Related]
16. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
[TBL] [Abstract][Full Text] [Related]
17. A novel mechanism for integrin-mediated ras activation in breast carcinoma cells: the alpha6beta4 integrin regulates ErbB2 translation and transactivates epidermal growth factor receptor/ErbB2 signaling.
Yoon SO; Shin S; Lipscomb EA
Cancer Res; 2006 Mar; 66(5):2732-9. PubMed ID: 16510594
[TBL] [Abstract][Full Text] [Related]
18. p130Cas promotes invasiveness of three-dimensional ErbB2-transformed mammary acinar structures by enhanced activation of mTOR/p70S6K and Rac1.
Tornillo G; Bisaro B; Camacho-Leal Mdel P; Galiè M; Provero P; Di Stefano P; Turco E; Defilippi P; Cabodi S
Eur J Cell Biol; 2011; 90(2-3):237-48. PubMed ID: 20961652
[TBL] [Abstract][Full Text] [Related]
19. Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiation.
Contessa JN; Abell A; Mikkelsen RB; Valerie K; Schmidt-Ullrich RK
Breast Cancer Res Treat; 2006 Jan; 95(1):17-27. PubMed ID: 16267617
[TBL] [Abstract][Full Text] [Related]
20. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis.
Maeshima Y; Sudhakar A; Lively JC; Ueki K; Kharbanda S; Kahn CR; Sonenberg N; Hynes RO; Kalluri R
Science; 2002 Jan; 295(5552):140-3. PubMed ID: 11778052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
